EYLEA HD / EYLEA
Revenue Exposure
31% of 2025 total revenues from U.S. EYLEA HD/EYLEA net sales; EYLEA U.S. sales fell 42% on competitive/biosimilar pressure with more biosimilars expected in H2 2026.
Relevance 95·Dependency 90·Confidence 98
Source evidence
“our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% and 42% of our total revenues, respectively.”
EYLEA HD and Dupixent
Demand Driver
Profitability and positive operating cash flow depend significantly on successful commercialization of EYLEA HD and Dupixent.
Relevance 95·Dependency 90·Confidence 95
Source evidence
“depends significantly on the success in commercializing our products, including EYLEA HD and Dupixent”
Dupixent, the largest Regeneron-discovered product with $17,806.7M global sales in 2025, is commercialized in collaboration with Sanofi; Regeneron records profit share/royalties and has supply obligations.
Relevance 95·Dependency 80·Confidence 100
Source evidence
“(b) In collaboration with Sanofi”
Sanofi collaboration, including profit share from commercialized products and R&D reimbursement, materially drives Regeneron's financial results.
Relevance 90·Dependency 85·Confidence 93
Source evidence
“the continuation of our collaborations, in particular with Sanofi and Bayer”
Dupixent is one of three products on which Regeneron is substantially dependent; Sanofi records U.S. sales and leads payor negotiations, creating reliance.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent.”
Bayer handles EYLEA HD/EYLEA commercialization outside the U.S.; termination on six or twelve months' notice would materially harm ex-U.S. revenue.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA HD and EYLEA outside the United States.”
Sanofi
Supplier Dependency
Sanofi records Dupixent U.S. sales, leads payor negotiations, and handles ex-U.S. commercialization; ongoing Antibody Collaboration Litigation adds relationship risk.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product.”
EYLEA biosimilars
Competitive Exposure
Post-May 2024 U.S. exclusivity expiration, FDA-approved EYLEA biosimilars (one launched; more expected H2 2026) will likely further reduce EYLEA/EYLEA HD sales and Bayer collaboration revenue ex-U.S.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“including competition from additional biosimilar versions of EYLEA expected to launch in the United States in the second half of 2026, which may have a material adverse impact on our results of operations.”
Limerick, Ireland
Manufacturing Dependency
Limerick, Ireland is one of two company-owned bulk drug manufacturing sites; business interruption or regulatory action there would impair product supply.
Relevance 90·Dependency 75·Confidence 97
Source evidence
“Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland”
Rensselaer, New York
Manufacturing Dependency
Rensselaer, NY is a primary bulk drug manufacturing site and houses a fill/finish facility still undergoing process validation; concentration of production creates supply interruption risk.
Relevance 90·Dependency 75·Confidence 97
Source evidence
“the manufacturing facilities in Rensselaer, New York and Limerick, Ireland”
U.S. drug pricing and reimbursement regulation
Regulatory Exposure
Sales depend on coverage/reimbursement by Medicare/Medicaid and private payors; drug price control measures could reduce pricing.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“drug price control measures that have been or may be enacted or introduced in the United States by various federal and state authorities”
Medicare and Medicaid reimbursement rules
Regulatory Exposure
Commercial success of Regeneron's products depends on reimbursement and copay assistance availability from Medicare, Medicaid, PBMs, and private payors.
Relevance 85·Dependency 70·Confidence 100
Source evidence
“coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties”
Regeneron and its collaborators/third parties depend on China-based suppliers for certain raw materials, products, services, and preclinical/clinical development activities; US-China tensions, tariffs, and the BIOSECURE Act could restrict this access.
Relevance 85·Dependency 60·Confidence 93
Source evidence
“depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities”
Limerick, Ireland
Manufacturing Dependency
Failures at Limerick, Ireland (or Rensselaer, NY) facilities would adversely affect ability to supply products.
Relevance 80·Dependency 75·Confidence 95
Source evidence
“failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland”
Regulatory approval
Regulatory Exposure
Pipeline value depends on uncertain regulatory approvals of new products and indications.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such products”
Bayer collaboration profit share and R&D reimbursement drive quarterly results.
Relevance 75·Dependency 60·Confidence 93
Source evidence
“the continuation of our collaborations, in particular with Sanofi and Bayer”
Aflibercept (EYLEA/EYLEA HD) outside the United States is in collaboration with Bayer, covering $3,506.3M of ex-U.S. EYLEA franchise sales in 2025.
Relevance 70·Dependency 60·Confidence 100
Source evidence
“(a) In collaboration with Bayer outside the United States.”
BIOSECURE Act
Regulatory Exposure
The recently enacted BIOSECURE Act, together with tariffs and trade restrictions, could restrict engagement of China-based suppliers or service providers for preclinical and clinical development programs.
Relevance 70·Dependency 50·Confidence 92
Source evidence
“the escalation of tariffs or other trade restrictions or the recently enacted BIOSECURE Act”
healthcare fraud and abuse laws
Legal Exposure
Business activities have been and may be challenged under U.S. federal or state and foreign healthcare laws, subjecting the company to civil or criminal proceedings, investigations, or penalties.
Relevance 65·Dependency 50·Confidence 90
Source evidence
“Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.”
Manufacturing continuity depends on availability of natural gas and other raw materials; supply chain interruptions or constraints including natural gas could halt production.
Relevance 60·Dependency 45·Confidence 90
Source evidence
“supply chain interruptions or constraints (including with respect to natural gas and other raw materials)”
tariffs and trade restrictions
Cost Driver
Tariffs and trade restrictions could impair Regeneron's ability to manufacture and manage supply chains for multiple products and candidates.
Relevance 60·Dependency 45·Confidence 100
Source evidence
“our ability to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions”
biological source raw materials
Raw Material Dependency
Products rely on biological-source raw materials (mammalian tissues, bovine serum, human serum albumin) subject to regulatory restrictions; forced substitution could delay development or commercial activities.
Relevance 55·Dependency 50·Confidence 92
Source evidence
“raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin”
Ireland
Manufacturing Dependency
2,149 of 15,410 full-time employees are employed in Ireland, representing a significant portion of industrial operations and product supply capability.
Relevance 55·Dependency 45·Confidence 90
Source evidence
“2,149 employed in Ireland”
EU General Data Protection Regulation
Regulatory Exposure
GDPR compliance obligations carry significant financial penalties and a private right of action for data subjects.
Relevance 55·Dependency 45·Confidence 100
Source evidence
“Violations of the GDPR carry significant financial penalties for noncompliance.”
siRNA gene silencing and other non-core modalities
Technology Dependency
Pursuit of drugs based on siRNA gene silencing, genome editing, and targeted viral-based gene delivery requires developing or acquiring additional manufacturing capabilities beyond established Trap/VelociSuite technologies.
Relevance 55·Dependency 40·Confidence 88
Source evidence
“such as siRNA gene silencing, genome editing, and targeted viral-based gene delivery and expression”